EP300 and acute myeloid leukemia: In addition, NEO2734 shows more potent anticancer effects than single-agent BRD4 or CBP/p300 inhibitors in lymphoma and acute myeloid leukemia cell lines, and exerts substantial anticancer effects in mouse models of lymphoma and acute myeloid leukemia [64] (Table 2).